Allarity Therapeutics Inc (ALLR)vsargenx NV ADR (ARGX)
ALLR
Allarity Therapeutics Inc
$1.12
-1.75%
HEALTHCARE · Cap: $17.28M
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates -59543% more annual revenue ($4.24B vs $-7.13M). ARGX leads profitability with a 30.5% profit margin vs 0.0%. ALLR trades at a lower P/E of 0.2x. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ALLR
Avoid23
out of 100
Grade: F
ARGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+97.7%
Fair Value
$39.10
Current Price
$1.12
$37.98 discount
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALLR
The strongest argument for ALLR centers on P/E Ratio, Price/Book.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bear Case : ALLR
The primary concerns for ALLR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ALLR profiles as a value stock while ARGX is a growth play — different risk/reward profiles.
ALLR carries more volatility with a beta of 0.24 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 23/100), backed by strong 30.5% margins and 73.0% revenue growth. ALLR offers better value entry with a 97.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Allarity Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Allarity Therapeutics A / S develops various therapeutic candidates for the treatment of cancer using complementary drug-specific diagnostics (cDx) generated by its drug response prediction technology. The company is headquartered in Horsholm, Denmark.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?